From 2011 to 2017, Stop-AD Centre enrolled a cohort of individuals in the research program called PREVENT-AD.

PREVENT-AD stands for PRe-symptomatic EValuation of Experimental or Novel Treatments for Alzheimer’s Disease.

The goal of this program is to study brain changes in cognitively healthy people over the age of 55. While some people in this age group begin to develop apparent memory problems, many more have subtle undetected brain changes that may mark the very beginning of Alzheimer Disease (AD), long before the onset of symptoms. With rapid advances in technology, such as high-resolution brain scanning methods or the precise examination of brain chemicals, we can now detect these early pieces of evidence of brain changes. What’s more, we can likely track these changes over time. Since these changes are more likely to occur in individuals who have had either a parent or sibling affected by AD, we required that our participants have a first-degree relative affected by AD. That’s why we label our research participants as ‘at-risk’  of developing AD.

The development of this program to study the presymptomatic phase of AD by measuring and tracking emergent and well-established AD-biomarkers (link to section biomarkers) offers a unique infrastructure to run clinical trials to test the potential of promising prevention strategies.

To achieve its endeavor, PREVENT-AD program follows research participants in a longitudinal observational cohort and has conducted two nested clinical trials:  INTREPAD, and DEPEND.